Exchange: NASDAQ·Updated 07:55 PM EST
ETON logo

ETON Eton Pharmaceuticals Inc

$60.85
$0.51
(0.83%)
Today
Closed $60.85
$0.19
(0.31%)
After Hours
Reported EarningsNov 5
Mkt Cap$1.76B
Vol562,661.00

About ETON

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.
35

Bearish Sentiment

How do you feel about ETON?

AMP19
$ETON I’m predicting market darling status here for years to come. Echo: Sean IS a Beast.
4
StocktwitsEarnings
$ETON Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.50 up 1150.00% YoY • Reported revenue of $57.92M up 157.88% YoY • Eton raised 2026 revenue guidance to more than $175M from more than $145M and expects at least a 40% Adjusted EBITDA margin, up from at least 35%.
2
shoc24
$ETON is ranked #6 in healthcare quality with a score of 89. I posted these rankings yesterday, but I think they're worth sharing again. I bought yesterday because money is made when the markets are down. I used Stock Meadow's scoring model to find what I'm buying.
1
oaksapollo
$ETON This is one of the best biotechs I've ever owned. Sean you have earned my undying loyalty. I will never sell my shares. NEVER!
1
AdamBrennan2
eton $ETON has burned cash for nine years and paid for it by issuing shares it sells rare disease drugs to pediatric endocrinologists through its own sales force. operating cash over the period is negative 35 million, and the share count is up 131.2% the money is going into manufacturing and the sales team for new launches either those launches grow into real cash flow, or this is a business that keeps asking shareholders to fund it $LLY $JNJ $AZN $NVO
shoc24
$ETON is ranked #8 in healthcare quality with a score of 89. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
openmarketalerts
$ETON — Director Casamento Charles J sold $5.3M of stock on Nov 10. • 80,555 shares at $66.35. • Sold near the 52-week high. • Stake down 100%.
dustlesspuma
🟢 $ETON 55C Nov 20 💰 $145,900 premium 💵 $0/contract 📊 0x Vol/OI 📍 Spot $145.9 💰 Large premium 🌊 Dark Flow | Options Flow
briefingcom
$ETON: Eton Pharma reported preliminary ET-700 data showing fewer treatment-related adverse events but significantly weaker copper inhibition than GALZIN.
G101SPM
$ETON $56.42 +9.27 Holding long lost at zero cost DAC (dollar average cost includes partial SELLS at proft). $00.00. Net gain on liquidations 711%. https://stocktwits.com/G101SPM/message/661876151 BRIEF:Preliminary pilot data showed ET-700 had 1 treatment-related adverse event in 12 participants versus 8 of 12 for GALZIN, with no serious adverse events reported. Hepatic copper uptake fell 12% with ET-700 versus 46% with GALZIN in the per-protocol analysis; placebo showed an 11% increase. In the intention-to-treat analysis, uptake fell 18% with ET-700 and 58% with GALZIN; GALZIN showed a greater effect than ET-700 with p=0.023. Eton plans additional study arms in 2027 to test faster-release formulations aimed at improving copper absorption inhibition while preserving tolerability.
AMP19
$ETON 70$ today. Not saying it will hold today, but Sean and the team are “just getting started”.
Rayvio_News_Filter
$ETON 🏥 Eton Pharmaceuticals, Inc. announced preliminary ET-700 pilot study results in 12 participants, with treatment-related adverse events in 1 of 12 ET-700 participants versus 8 of 12 GALZIN participants and hepatic copper uptake decreases of 12% with ET-700, 46% with GALZIN, and an 11% increase with placebo. Selected from hundreds of headlines
G101SPM
$ETON $52.47 ask Holding long position at zero cost https://stocktwits.com/G101SPM/message/661876151 BRIEF: Eton licensed Baylor College of Medicine patent rights covering IGF-1 use in spasms and is advancing ET-900, which uses mecasermin, the active ingredient in Eton's marketed INCRELEX. A research IND has been submitted to the FDA for an investigator-sponsored Phase 2 study in children with refractory epileptic spasms; first patient dosing is planned in Q1 2027. The University of Chicago-sponsored trial is expected to enroll up to 20 patients ages 2-18 across University of Chicago, Baylor, and UCLA, with efficacy, safety, tolerability, EEG, and adaptive functioning endpoints. Eton said it retains commercial rights to ET-900; preclinical Baylor/Texas Children's work showed about a 50% reduction in daily spasms and elimination of spasms in 20% of treated animals.
Rayvio_News_Filter
$ETON 🤝 Eton Pharmaceuticals, Inc. licensed patent rights from Baylor College of Medicine covering IGF-1 for infantile and epileptic spasms and initiated ET-900, with an IND submitted to FDA for an investigator-sponsored Phase 2 study in children with refractory epileptic spasms. Prioritized by relevance

Advertisement|Remove ads.